Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company harnesses the immune system through its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate both innate and adaptive immune responses against tumors. Key pipeline candidates include BDC-1001, targeting HER2-positive solid tumors such as breast, colorectal, endometrial, and gastroesophageal cancers; BDC-3042, an agonist antibody targeting Dectin-2 on tumor-associated macrophages for tumors like head and neck, non-small cell lung, ovarian, and triple-negative breast cancers; and BDC-4182, a next-generation ISAC targeting claudin 18.2, overexpressed in gastric, gastroesophageal junction, and pancreatic cancers. Bolt Biotherapeutics Inc. maintains collaborations with partners including Toray Industries, Genmab, and Innovent Biologics to advance its ISAC technologies. Incorporated in 2015 and headquartered in Redwood City, California, the company operates in the biotechnology sector of healthcare, emphasizing myeloid biology and immuno-oncology drug development.